BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

VolverVolver

Resultados 41 resultados LastUpdate Última actualización 20/01/2022 [10:51:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 2 nextPage   por página


PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY IN ALZHEIMER'S DISEASE

NºPublicación: US2022010004A1 13/01/2022

Solicitante:

AXON NEUROSCIENCE SE [CY]

KR_20210099167_A

Resumen de: US2022010004A1

The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or pep tide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.

traducir

BLOOD TEST FOR SCREENING OUT AMYLOID AND ALZHEIMER'S DISEASE PRESENCE

NºPublicación: JP2022001869A 06/01/2022

Solicitante:

ユニバーシティーオブノーステキサスヘルスサイエンスセンターアットフォートワースUNIVERSITYOFNORTHTEXASHEALTHSCIENCECENTERATFORTWORTH

JP_2019522193_A

Resumen de: WO2017223291A1

The present invention includes a method for excluding patients from the need for further analysis of Alzheimer's Disease comprising: obtaining a blood or serum sample from a patient in a primary care setting; determining the expression levels of at least 4 of the following proteins: FABP, beta 2 microglobulin, PPY, soluble tumor necrosis factor receptor 1 (sTNFRl), CRP, VCAM-1, thrombopoietin, α2 macroglobulin, eotaxin 3, tumor necrosis factor-alpha (TNF-α), tenascin C (TNC), IL-5, IL-6, IL-7, IL-10, IL-18, 1309, Factor VII, thymus and activation-regulated chemokine (TARC), serum amyloid A (SAA), and intercellular cell-adhesion molecule-1 (ICAM-1); comparing the level of expression from the sample with a statistically locked-down, multi-ethnic, broad age spectrum statistical sample; and determining if the patient is excluded from further testing for Alzheimer's Disease, thereby eliminating the need for further testing of the patient.

traducir

BIOMARKER PROTEINS FOR DIAGNOSING ALZHEIMER'S DEMENTIA AND USE THEREOF

NºPublicación: US2022003787A1 06/01/2022

Solicitante:

UNIV AJOU IND ACADEMIC COOP FOUND [KR]

WO_2020091222_PA

Resumen de: US2022003787A1

Provided are a composition for diagnosing Alzheimer's dementia, the composition including an agent for measuring levels of mRNAs of one or more genes selected from the group consisting of neurotrimin (NTM), peptidylglycine-α-amidating monooxygenase (PAM), receptor-type tyrosine-protein phosphatase N2 (PTPRN2), opioid-binding protein/cell adhesion molecule (OPCML), 14-3-3 protein ζ/δ (YWHAZ), chromogranin-A (CHGA), and secretogranin-1 (CHGB), or levels of proteins expressed therefrom; a kit for diagnosing Alzheimer's dementia, the kit including the composition; and a method of providing information for the diagnosis of Alzheimer's dementia, the method including the steps of measuring the levels of mRNAs of the genes or the levels of proteins expressed therefrom, and comparing the measured levels with those measured in a sample isolated from a normal individual.The composition for diagnosing Alzheimer's dementia of the present disclosure may be used to diagnose Alzheimer's dementia with high sensitivity and specificity by measuring expression levels of mRNAs of the genes or expression levels of proteins expressed therefrom, and then comparing the levels with those of a normal control group.

traducir

5-HT2A SEROTONIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR USE IN REDUCING AMYLOID-BETA PEPTIDES AND ACCUMULATION OF AMYLOID PLAQUES

NºPublicación: US2022000852A1 06/01/2022

Solicitante:

ACADIA PHARM INC [US]

WO_2017172757_PA

Resumen de: US2022000852A1

Described are compounds and compositions for use in methods for reducing the rate of accumulation of amyloid plaques in a subject by administering a 5-HT2A serotonin receptor inverse agonist or antagonist, or pharmaceutically acceptable salts thereof.

traducir

METHODS FOR DIAGNOSING ALZHEIMER'S DISEASE BASED ON CELL GROWTH RATE, SIZE AND PROTEIN AMOUNT

NºPublicación: EP3931574A1 05/01/2022

Solicitante:

NEURODIAGNOSTICS LLC [US]

WO_2020176573_A1

Resumen de: WO2020176573A1

This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject. These methods comprise measuring the growth rate, size and/or protein amount of a subject's skin fibroblasts and/or lymphocytes, and determining whether these values differ in certain ways from those of corresponding non-Alzheimer's disease dementia cells. This invention also provides methods for determining whether an asymptomatic human subject is at risk from becoming afflicted with Alzheimer's disease.

traducir

METHOD OF INHIBITING TAU PHOSPHORYLATION

NºPublicación: JP2022000421A 04/01/2022

Solicitante:

キャッサバサイエンシズインコーポレイテッド

US_2021389298_A1

Resumen de: US2014018341A1

A method of inhibiting phosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.

traducir

Method for treating Alzheimer's disease by inhibiting uptake of amino acids by T cells

NºPublicación: CN113874038A 31/12/2021

Solicitante:

上海绿谷制药有限公司中国科学院上海药物研究所

WO_2021023238_A9

Resumen de: CN112336859A

The invention relates to the treatment of Alzheimer's disease. The invention provides an application of a reagent an agent for inhibiting the uptake of amino acids by initial T cells to preparation ofa medicament for the treatment of Alzheimer's disease in a subject.

traducir

BIOMARKERS FOR THE DIAGNOSIS AND CHARACTERIZATION OF ALZHEIMER'S DISEASE

NºPublicación: US2021405074A1 30/12/2021

Solicitante:

KADDURAH DAOUK RIMA F [US]
TOLEDO JON B [US]
ARNOLD MATTHIAS [DE]
KASTEMUELLER GABI [DE]
BAILLIE REBECCA A [US]
HAN XIANLIN [US]
THOMPSON WILL [US]
ST JOHN WILLIAMS LISA [US]
KOAL THERESE [AT]
NHO KWANGSIK [US]
MOSELEY M ARTHUR [US]
SAYKIN ANDREW J [US]
DORAISWAMY PUDUGRAMAM MURALI [US]

WO_2018049268_PA

Resumen de: US2021405074A1

Embodiments of the present disclosure relate generally to the analysis and identification of global metabolic changes in Alzheimer's disease (AD). More particularly, the present disclosure provides materials and methods relating to the use of metabolomics as a biochemical approach to identify peripheral metabolic changes in AD patients and correlate them to cerebrospinal fluid pathology markers, imaging features, and cognitive performance. Defining metabolic changes during AD disease trajectory and their relationship to clinical phenotypes provides a powerful roadmap for drug and biomarker discovery.

traducir

Alpha-Synuclein Detection Assay and Method for Diagnosing Alpha-Synucleinopathies

NºPublicación: US2021405069A1 30/12/2021

Solicitante:

UNIV COURT UNIV OF EDINBURGH [GB]

US_2021263049_A1

Resumen de: US2021405069A1

A method of detecting the presence of alpha-synuclein aggregation in a biological sample is provided whereby a biological sample is mixed with a reaction sample comprising a population of beads, a fluorophore adapted to bind to protein aggregates and to increase fluorescence when bound to protein aggregates, and alpha-synuclein or a fragment or variant thereof to form a reaction mixture, the reaction mixture is illuminated and at the same time incubated with intermittent agitation cycles, wherein a significant increase in the fluorescence of the reaction mixture during incubation is indicative of the presence of aggregates of alpha-synuclein in the biological sample. Method of diagnosing alpha-synucleinopathies such as Parkinson's disease or Dementia with Lewy Bodies.

traducir

METHOD FOR MEASURING Aß PEPTIDE

NºPublicación: US2021405068A1 30/12/2021

Solicitante:

SYSMEX CORP [JP]

CN_113848258_PA

Resumen de: US2021405068A1

Disclosed is a method for measuring an Aβ peptide, comprising: mixing a blood sample comprising an Aβ peptide and an antibody that specifically binds to the Aβ peptide to form a complex of the Aβ peptide and the antibody; releasing the AP peptide from the complex with a basic solution comprising an organic solvent; and measuring the released Aβ peptide by mass spectrometry.

traducir

METHOD FOR MEASURING Aß PEPTIDE

NºPublicación: EP3929589A1 29/12/2021

Solicitante:

SYSMEX CORP [JP]

US_2021405068_A1

Resumen de: US2021405068A1

Disclosed is a method for measuring an Aβ peptide, comprising: mixing a blood sample comprising an Aβ peptide and an antibody that specifically binds to the Aβ peptide to form a complex of the Aβ peptide and the antibody; releasing the AP peptide from the complex with a basic solution comprising an organic solvent; and measuring the released Aβ peptide by mass spectrometry.

traducir

METHOD FOR MEASURING Aß PEPTIDE

NºPublicación: CN113848258A 28/12/2021

Solicitante:

希森美康株式会社

US_2021405068_A1

Resumen de: US2021405068A1

Disclosed is a method for measuring an Aβ peptide, comprising: mixing a blood sample comprising an Aβ peptide and an antibody that specifically binds to the Aβ peptide to form a complex of the Aβ peptide and the antibody; releasing the AP peptide from the complex with a basic solution comprising an organic solvent; and measuring the released Aβ peptide by mass spectrometry.

traducir

COMPOSITION FOR DETECTING HYDROGEN SULFIDE OR MEASURING HYDROGEN SULFIDE CONCENTRATION AND COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT FOR DIAGNOSING OR IMAGING IN VIVO INFLAMMATION, TISSUES HAVING HYPOXIC DAMAGE, OR CANCER

NºPublicación: JP2021536508A 27/12/2021

Solicitante:

ソウル大学校産学協力団SEOULNATIONALUNIVERSITYR&DBFOUNDATION

US_2021190759_A1

Resumen de: WO2020055175A1

The present invention relates to a composition for detecting hydrogen sulfide or measuring a concentration of hydrogen sulfide, and a composition comprising same as an effective ingredient for diagnosing or imaging in vivo inflammation, tissues having hypoxic damage, or cancer. The composition for detecting hydrogen sulfide or measuring a concentration of hydrogen sulfide according to the present invention, which comprises the compound represented by chemical formula 1 (99mTc-alpha-hydroxy acid) having alpha-hydroxy acid labeled with 99mTc, enables the detection or concentration measurement of hydrogen sulfide in in-vitro and in-vivo levels and, as such, can be advantageously used for detecting hydrogen sulfide and measuring a concentration of hydrogen sulfide and furthermore for discovering biological roles of hydrogen sulfide in vivo, especially, for detecting, imaging, and quantitatively measuring hydrogen sulfide in a disease selected from the group consisting of angiogenesis, inflammation, cancer, Alzheimer's disease, cardiovascular ischemia, and cerebrovascular ischemia, or in hypoxic tissues.

traducir

PROTEIN ANTIGEN COMBINATION, DETECTION METHOD AND TESTING KIT USING THE SAME

NºPublicación: US2021396769A1 23/12/2021

Solicitante:

SHANGHAI ZHONGQI BIOTECHNOLOGY CO LTD [CN]

Resumen de: US2021396769A1

A protein antigen combination for detecting Alzheimer's disease autoantibodies in human serum sample and an application thereof are disclosed. The protein antigen combination includes at least two protein fragments selected from the following proteins: MAPT, ADARB1, P21, DNAJC8, RAGE, ASXL1, and JMJD2D. Based on the protein antigen composition, a kit for diagnosis, especially for early diagnosis of Alzheimer's disease or its related risks, can be prepared. By using the protein antigen composition provided by the invention, early Alzheimer's disease can be quickly and accurately diagnosed, which has important practical significance.

traducir

METHODS AND COMPOSITIONS COMPRISING TAU OLIGOMERS

NºPublicación: US2021395319A1 23/12/2021

Solicitante:

OLIGOMERIX INC [US]

US_2012029169_PA

Resumen de: US2021395319A1

Tau protein has a causative role in Alzheimer's disease and multiple other neurodegenerative disorders exhibiting tau histopathology collectively termed tauopathies. The primary function of tau protein is to facilitate assembly and maintenance of microtubules in neuronal axons. In the disease process tau protein becomes modified, loses its affinity to microtubules and accumulates in the cell body where it forms aggregates. The large neurofibrillary tangles formed from tau protein assembled into filaments were thought to be the pathological structure of tau. However, more recent work indicates that smaller, soluble oligomeric forms of tau are best associated with neuron loss and memory impairment. Here, novel compositions of tau oligomers and novel mechanisms for tau oligomer nucleation, extension and termination are taught. Methods for producing and purifying these structures for the development of small molecule and immunotherapeutics as well as antibodies for biomarkers of neurodegenerative diseases are taught.

traducir

A DRUG SCREENING PLATFORM FOR ENDOSOMAL ENHANCERS TO TREAT ALZHEIMER'S DISEASE

NºPublicación: WO2021255027A1 23/12/2021

Solicitante:

UNIV AARHUS [DK]

Resumen de: WO2021255027A1

The present invention relates to a sorLA-based drug screening platform for use in screening compound libraries for an effect on endosomal activity.

traducir

BIOMARKER FOR DIAGNOSIS OF ALZHEIMER'S DISEASE USING ORAL BACTERIA COMMUNITY, AND USE FOR SAME

NºPublicación: WO2021256710A1 23/12/2021

Solicitante:

NAT UNIV PUSAN IND UNIV COOP FOUND [KR]

KR_102225447_B1

Resumen de: WO2021256710A1

The present invention relates to a biomarker for the diagnosis and degree of risk prediction of Alzheimer's disease by using oral microbiomes, and a use for same in the diagnosis and prediction of Alzheimer's disease.

traducir

HUMANIZED ANTI-AΒ MONOCLONAL ANTIBODY AND USE THEREOF

NºPublicación: EP3925975A1 22/12/2021

Solicitante:

CHANGCHUN GENESCIENCE PHARMACEUTICAL CO LTD [CN]

CN_111518205_A

Resumen de: WO2020156221A1

The present invention relates to the technical field of antibody drugs, and in particular, to a humanized anti-Aβ monoclonal antibody and use thereof. The humanized anti-Aβ monoclonal antibody provided in the present invention can inhibit polymerization of Aβ monomer, can promote phagocytosis of Aβ by macrophages, can protect neural cells from Aβ toxicity, and can be used for treating and diagnosing diseases and conditions related to amyloidosis, such as Alzheimer's disease.

traducir

Alzheimer's Disease Assay in a Living Patient

NºPublicación: US2021389298A1 16/12/2021

Solicitante:

PAIN THERAPEUTICS INC [US]

JP_2022000421_A

Resumen de: US2021389298A1

An assay for Alzheimer's disease pathology (AD) in a living patient is disclosed wherein an amount of α7nAChR or TLR4 in a FLNA-captured protein complex or α7nAChR in an Aβ-captured protein complex or α7nAChR-FLNA, TLR4-FLNA and/or α7nAChR-Aβ42 complex present as a protein-protein complex in a sample is determined and compared to the amount in a standard sample from a person free of AD pathology. An amount greater than in the standard sample indicates AD pathology. Also disclosed is an assay predictive of prognosis for treatment with a medicament in which the amount of an above protein or protein complex is determined and compared to an amount determined in the presence of a medicament that binds to a FLNA pentapeptide and contains at least four of the six pharmacophores of FIGS. 7-12. An amount of protein or protein complex determined in the presence of the medicament less than the first determined amount indicates a favorable treatment prognosis.

traducir

METHOD FOR DETECTING SOLUBLE OLIGOMERIC AMYLOID BETA

NºPublicación: US2021386879A1 16/12/2021

Solicitante:

UNIV NORTHWESTERN [US]

US_2017209604_A1

Resumen de: US2021386879A1

A method for detecting soluble oligomeric amyloid β in a subject is provided.

traducir

INHIBITION OF RIP KINASES FOR TREATING NEURODEGENERATIVE DISORDERS

NºPublicación: JP2021535152A 16/12/2021

Solicitante:

ザ・ジョンズ・ホプキンス・ユニバーシティー

US_2021322427_A1

Resumen de: WO2020047414A1

Provided herein are compositions comprising a RIPK2 inhibitor and methods of using the RIPK2 inhibitor for treating or preventing neurodegenerative diseases or disorders. Also provided herein are methods of screening or identifying therapeutic agents useful for treating or preventing neurodegenerative diseases or disorders.

traducir

AMYLOID BETA DETECTION BY MASS SPECTROMETRY

NºPublicación: JP2021192038A 16/12/2021

Solicitante:

クエストダイアグノスティックスインヴェストメンツエルエルシー

MX_2018004017_A

Resumen de: US2017089917A1

Provided are methods for the detection or quantitation of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (Aβ42) to amyloid beta 40 (Aβ40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.

traducir

EMPTY POROUS PARTICLES FOR USE IN TREATMENT, PREVENTION AND/OR POSTPONEMENT OF DEGENERATION OF NEURODEGENERATIVE DISEASES, NEURONS AND GLIA.

NºPublicación: KR20210153080A 16/12/2021

Solicitante:

나노로지카에이비

CN_113454456_A

Resumen de: WO2020212418A1

The present invention relates to empty porous particles having a diameter between 0.1 and 1000 µm, as measured by e.g. SEM, for use in diagnosis, prevention and/or postponement of neurodegenerative diseases, or for prevention and/or postponement of degeneration of neurons and glia. The invention also relates to a method of identifying biomarkers for use in diagnosis.

traducir

ANTI-EMAP II ANTIBODY AND USE THEREOF

NºPublicación: US2021388076A1 16/12/2021

Solicitante:

HUB BIOTECH CO LTD [KR]

US_2020040071_A1

Resumen de: US2021388076A1

The present invention relates to an anti-EMAP II antibody or an antigen-binding fragment thereof, a nucleic acid molecule for coding the same, or a preparation method thereof. Also, the present invention provides a method for using the anti-EMAP II antibody or the antigen-binding fragment thereof in preventing, treating or diagnosing EMAP II-mediated diseases, for example, TNF-α-mediated disease or Alzheimer's disease. Furthermore, the present invention provides a method for using the anti-EMAP II antibody or the antigen-binding fragment thereof in detecting or quantifying an EMAP II antigen. The antibody of the present invention may exhibit a more improved antigen-binding capacity compared to existing anti-EMAP antibodies and may treat the TNF-α-mediated disease more effectively.

traducir

COMPOSITION COMPRISING OSTEOPONTIN INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTION, ALLEVIATION, OR TREATMENT OF NEURODEGENERATIVE DISEASE

Nº publicación: WO2021246744A1 09/12/2021

Solicitante:

CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION [KR]

Resumen de: WO2021246744A1

The present invention relates to a pharmaceutical composition comprising an agent inhibiting gene expression or protein activity of osteopontin as an active ingredient for preventing or treating neurodegenerative disease. According to the present invention, there is an effect of suppressing amyloid beta (Aβ)-induced neuronal cell death by downregulating the expression or activity of osteopontin. In addition, an inhibitor against the expression or activity of osteopontin decreases a level of pro-inflammatory proteins and conversely, increases a level of anti-inflammatory proteins. Therefore, it is expected that the present invention can be advantageously used as a therapeutic agent for various neurodegenerative diseases including Alzheimer's disease.

traducir

Página1 de 2 nextPage por página

punteroimgVolver